6th Targeted Radiopharmaceuticals Summit Europe 2024

This year has been the year for radiopharmaceuticals, with market projections estimating to grow to $39 billion by 2032. More patients are being treated by Pluvicto and Lutathera than ever before, companies advancing their pipelines across a range of targeting moieties, radioisotopes and novel targets including DLL3 and NTSR1- and that's not to mention the flood of billion-dollar acquisitions and investments from Novartis, AstraZeneca, Eli Lilly and BMS strengthening the field! The 6th Targeted Radiopharmaceuticals Summit Europe is the longest standing industry focused meeting delivering an end-to-end overview of this highly competitive and dynamic landscape.

Uncovering novel target development beyond validated PSMA and SSTR2 to reach more indications, expanding targeting moieties to enhance tumour penetration and revealing key case studies from designing a first in human radiopharmaceutical trial as well as applying dosimetry to optimize dosing. The community will explore how Europe can keep up with fast paced innovation by reaching regulatory clarity while analysing the US-Europe intersection across pressing clinical and supply chain challenges to keep your global trials moving. Bringing together insights from the leading radiopharmaceutical minds across pharma, biotech, academia, and clinicians from discovery, preclinical, clinical, CMC and supply chain this is your opportunity to network and learn from the experts.

Gathering world-class speakers to address the most exciting opportunities and challenges spanning novel targeting mechanisms, alpha vs beta emitters, nuclear medicine clinical expertise, isotope supply, European logistics chains as well as pricing and reimbursement- don't miss the biggest edition of the 6th Targeted Radiopharmaceuticals Summit to date!

URLs:
Website: https://go.evvnt.com/2581668-0?pid=10018
Tickets: https://go.evvnt.com/2581668-2?pid=10018
Brochure: https://go.evvnt.com/2581668-4?pid=10018

Prices:
Drug Developer Conference Only: EUR 2699.00,
Drug Developer Conference + Workshop Day: EUR 3697.00,
Academic Conference Only: EUR 2299.00,
Academic Conference + Workshop Day: EUR 3097.00,
Solution Provider Conference Only: EUR 3299.00,
Solution Provider Conference + Workshop Day: EUR 4497.00

Speakers: Bernard Lambert, Chief Technology Officer, Mariana Oncology, Caitlyn Harvey, Vice President, Head of CMC, Convergent Therapeutics, Caroline Stokke, Head of Section, Norway, Christopher Leamon, Chief Scientific Officer, Fusion Pharmaceuticals, Daniel Rossetto, Senior Vice President and Head Of Supply Chain and External Manufacturing, ARTBIO, Daniel Steiner, Senior Vice President Research and Technology, Molecular Partners AG, Dirk Pleimes, Chief Medical and Scientific Officer, PentixaPharm GmbH, Dr. Manfred, Rüdiger CEO, Ariceum, Evrim Gurpinar, Senior Director, Oncology R and D Business Development, AstraZeneca, Francesco De Rose, Head of Pharmaceutical Development, Nuclidium, Glenn Flux, Head of Radioisotope Physics, Institute of Cancer Research, Goekben Koca, Chief Medical Officer, Mariana Oncology, Jakub Simecek, Chief Executive Officer, TRIMT, Jasminka Taleska, Global Director RLT HCS Readiness and RLT Policy Strategy, Novartis AG, Jeevan Virk, Vice President - Radioligand Therapy (RLT) Therapeutic Area Strategy Head, Novartis AG, Jenny Karlsson, Senior Director Targeted Radiopharmaceuticals, Bayer, Jens De Vos, Co-Founder and Head of Research and Development and Operations, Precirixv, Jeremy Paull, Vice President - Development and Regulatory Affairs, Starpharma Ltd., Julie Nonnekens, Associate Professor Radiobiology of Radionuclide Therapy, Erasmus MC Cancer Institute, Julien Torgue, Chief Scientific Officer, OranoMed, Katarina Sjoegreen, Gleisner Professor, Lund University, Ken Herrmann, Professor , University Hospital Essen, Laila Quere, Co-Founder and Chief Executive Officer, Aken medical, Laurent Durous, Process Analytical Technology Scientist, Bayer, Leonhard Schaetz, International Head Health System Readiness and Partnership (RLT), Novartis AG, Luke Brzozowski Executive Director, Translational Research, Core Facilities, Theranostics, University Health Network Canada, Marc Robillard, Chief Executive Officer, Tagworks Pharmaceuticals, Marika Nestor, Chief Executive Officer, Akiram Therapeutics AB, Michel Afargan, Head Drug Development, Starget Pharma, Ming Xu, Vice President, Product Team Leader (PTL) for RED Oncology, Bayer, Munir Ghesani, Chief Medical Officer, Icahn School of Medicine at Mount Sinai, Neydher Berroteran, Infante Director - Chemistry, Manufacturing and Controls, PentixaPharm GmbH, Nina Eissler, Director Translational Medicine, Affibody AB, Riccardo Canevari, CEO Radiopharm Theranostics, RadioPharm Theranostics, Samuele Cazzamalli, Head of Chemistry, Philochem, Sigal Kalmanson Cusnir, Chief Executive Officer, Starget Pharma, Vicki Jardine, Vice President Clinical Development, ARTBIO, Vimal Patel, Vice President, CMC RadioPharm Theranostics, Vineet Prakash, Medical Consultant, Royal Surrey County Hospital